nalidixic acid has been researched along with linezolid in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bachand, B; Barnes, MH; Bethell, R; Brown, NC; Butler, MM; Cadilhac, C; Charron, S; Comstock, J; Dix, EJ; Foster, KA; Holm, KA; LaMarr, WA; Lamothe, S; Long, ZY; Manikowski, A; Motorina, I; Storer, R; Tarantino, PM; Wright, GE; Xu, WC; Zhi, C | 1 |
| Beceiro, A; Bou, G; Canle, D; Fernández, A; Lasa, I; Latasa, C; Mallo, S; Molina, F; Pérez, A; Pérez, S; Poza, M; Tomás, Mdel M; Villanueva, R | 1 |
| Bammert, GF; Banitt, LS; Barbachyn, MR; Boyle, TP; Bundy, GL; Dolak, LA; Ford, CW; Graber, DR; Hamel, JC; Han, F; Harris, DW; Hromockyj, AE; Hurd, AR; Kamilar, GM; Marotti, KR; Martin, GE; Miller, AA; Mott, JE; Munzner, JB; Palmer, JR; Ruble, JC; Seest, EP; Skepner, JE; Sweeney, MT; Zhong, WZ; Zurenko, GE | 1 |
| Bohnert, JA; Karamian, B; Nikaido, H | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for nalidixic acid and linezolid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 other study(ies) available for nalidixic acid and linezolid
| Article | Year |
|---|---|
Hybrid antibacterials. DNA polymerase-topoisomerase inhibitors.
Topics: Aniline Compounds; Animals; Anti-Bacterial Agents; DNA Polymerase III; Drug Resistance, Bacterial; Gram-Positive Bacteria; Male; Mice; Staphylococcal Infections; Staphylococcus aureus; Structure-Activity Relationship; Topoisomerase II Inhibitors; Toxicity Tests, Acute; Uracil | 2006 |
Cloning, nucleotide sequencing, and analysis of the AcrAB-TolC efflux pump of Enterobacter cloacae and determination of its involvement in antibiotic resistance in a clinical isolate.
Topics: Bacterial Proteins; Base Sequence; beta-Lactamases; Carrier Proteins; Cloning, Molecular; DNA, Bacterial; Drug Resistance, Bacterial; Enterobacter cloacae; Enterobacteriaceae Infections; Genes, MDR; Genetic Vectors; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Porins | 2007 |
Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Bacteria; Bacterial Infections; Bacterial Proteins; Cell Line; Cell Proliferation; Metabolic Clearance Rate; Mice; Microbial Sensitivity Tests; Molecular Structure; Staphylococcus aureus; Stereoisomerism; Topoisomerase II Inhibitors | 2008 |
Optimized Nile Red efflux assay of AcrAB-TolC multidrug efflux system shows competition between substrates.
Topics: Anti-Bacterial Agents; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Chlortetracycline; Dipeptides; Doxorubicin; Doxycycline; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Proteins; Minocycline; Onium Compounds; Organophosphorus Compounds; Tetracycline | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |